<DOC>
	<DOCNO>NCT00566020</DOCNO>
	<brief_summary>This study plan assess long-term safety lamotrigine Japanese patient bipolar I disorder continue 52-week extension upon completion double-blind comparative study ( Study No . : SCA104779 ( NCT00550407 ) ) , i.e . patient receive addition additional treatment intervene mood episode double-blind phase patient complete double-blind phase .</brief_summary>
	<brief_title>A Clinical Evaluation Of BW430C ( Lamotrigine ) In Bipolar I Disorder- Long-term Extension Of Study SCA104779 ( NCT00550407 ) -</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Of subject participate precede doubleblind study , judge investigator/subinvestigator well tolerated doubleblind treatment eligible 52week extension treatment Sex : either sex . Female childbearing potential eligible inclusion study . However negative pregnancy test start study , agree pregnancy test time point determine study assessment procedure practice one follow method contraception start study end followup examination : Abstinence Oral contraceptive , either combined progestogen alone ( except Dosage Adjustment Phase ) Injectable progestogen Implants levonorgestrel Estrogenic vaginal ring ( except Dosage Adjustment Phase ) Percutaneous contraceptive patch ( except Dosage Adjustment Phase ) Intrauterine device ( IUD ) intrauterine system ( IUS ) meet SOP effectiveness criterion state product label Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study , male sole partner subject Double barrier method : condom occlusive cap ( diaphragm cervical / vault cap ) plus spermicidal agent ( foam / gel / film / cream / suppository ) In/Out patient : Either Informed consent : subject capable give write informed consent Has score 3 item HAMD relate suicide high suicidal risk judgment investigator/subinvestigator Has history severe rash rash due antiepileptic drug Patients severe hepatic/renal/cardiac/pulmonary disorder hematopoietic disorder . The severity refers Grade 3 accord `` Classification Severity Adverse Experiences '' ( PAB/SD Notification No . 80 , date 29 June 1992 ) Patients less 5 year remission history clinically significant malignancy ( e.g . basal cell squamous cell skin cancer , insitu carcinoma cervix prostate CA situ ) Patients chronic hepatitis typeB /or typeC positive hepatitis B surface antigen （HBsAg）and/or hepatitis C antibody Has acute chronic illness likely impair drug absorption , distribution , metabolism excretion unstable physical symptom likely require hospitalisation participation study Female patient pregnant lactating , may pregnant , plan pregnancy study Has history current diagnosis epilepsy Has receive investigational drug within 30 day screen Patients history drug allergy ingredient testdrug Patients investigator subinvestigator considers ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Open-label extension</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Lamotrigine</keyword>
	<keyword>Safety</keyword>
	<keyword>Bipolar I disorder</keyword>
</DOC>